A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Public ClinicalTrials.gov record NCT07227597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
Study identification
- NCT ID
- NCT07227597
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Carboplatin Drug
- Etoposide Drug
- Gocatamig Drug
- I-DXd Drug
- Rescue Medications Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 28, 2026
- Primary completion
- Nov 28, 2030
- Completion
- Dec 29, 2030
- Last update posted
- May 6, 2026
2026 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Orlando Health Cancer Institute ( Site 0108) | Orlando | Florida | 32806 | Recruiting |
| Saint Elizabeth Medical Center Edgewood ( Site 0112) | Edgewood | Kentucky | 41017 | Recruiting |
| Washington University School of Medicine ( Site 0134) | St Louis | Missouri | 63110 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) | Hackensack | New Jersey | 07601 | Recruiting |
| Avera Cancer Institute- Research ( Site 0104) | Sioux Falls | South Dakota | 57105 | Recruiting |
| The University of Tennessee Medical Center ( Site 0120) | Knoxville | Tennessee | 37920 | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | 37203 | Recruiting |
| Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227597 live on ClinicalTrials.gov.